SMTL ID : 6prz.1

XFEL beta2 AR structure by ligand exchange from Alprenolol to Alprenolol.

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.80 Å

Oligo State

monomer

Ligands

1 x JTZ: (2S)-1-[(1-methylethyl)amino]-3-(2-prop-2-en-1-ylphenoxy)propan-2-ol(Non-covalent)

JTZ.1: 17 residues within 4Å: Chain A: W.133, T.134, D.137, V.138, V.141, F.217, Y.223, A.224, S.227, S.228, S.231, W.438, F.441, F.442, N.445, N.464, Y.468 11 PLIP interactions: 11 interactions with chain A Hydrophobic interactions: A:W.133, A:W.133, A:T.134, A:V.138, A:F.217, A:Y.223 Hydrogen bonds: A:N.464, A:N.464, A:Y.468, A:Y.468 pi-Stacking: A:F.442

1 x CLR: CHOLESTEROL(Non-covalent)

CLR.2: 9 residues within 4Å: Chain A: Y.94, T.97, S.98, C.101, R.175, I.178, L.179, W.182 Ligands: OLC.3 3 PLIP interactions: 3 interactions with chain A Hydrophobic interactions: A:T.97, A:I.178, A:W.182

3 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)

OLC.3: 4 residues within 4Å: Chain A: I.79, Q.89, T.97 Ligands: CLR.2 1 PLIP interactions: 1 interactions with chain A Hydrogen bonds: A:Q.89 OLC.4: 6 residues within 4Å: Chain A: V.150, V.153, D.154, F.157, L.168, L.169 3 PLIP interactions: 3 interactions with chain A Hydrophobic interactions: A:V.150, A:V.153, A:L.169 OLC.5: 7 residues within 4Å: Chain A: F.247, F.416, K.425, G.428, I.429, G.432, T.433 No protein-ligand interaction detected (PLIP)

2 x OLA: OLEIC ACID(Non-covalent)

OLA.6: 3 residues within 4Å: Chain A: V.72, T.80, L.108 3 PLIP interactions: 3 interactions with chain A Hydrophobic interactions: A:V.72, A:L.108 Hydrogen bonds: A:T.80 OLA.7: 4 residues within 4Å: Chain A: Y.156, F.241, V.242, R.245 4 PLIP interactions: 4 interactions with chain A Hydrophobic interactions: A:Y.156, A:Y.156, A:F.241 Salt bridges: A:R.245

4 x SO4: SULFATE ION(Non-functional Binders)

SO4.8: 7 residues within 4Å: Chain A: T.90, V.91, T.92, R.155, Y.165, Q.166, S.167 7 PLIP interactions: 7 interactions with chain A Hydrogen bonds: A:T.90, A:V.91, A:T.92, A:T.92, A:Y.165, A:S.167 Salt bridges: A:R.155 SO4.9: 4 residues within 4Å: Chain A: F.416, K.422, K.425, R.480 3 PLIP interactions: 3 interactions with chain A Salt bridges: A:K.422, A:K.425, A:R.480 SO4.10: 5 residues within 4Å: Chain A: F.367, T.368, N.369, S.370, N.385 5 PLIP interactions: 5 interactions with chain A Hydrogen bonds: A:F.367, A:N.369, A:N.369, A:S.370, A:N.385 SO4.11: 4 residues within 4Å: Chain A: T.395, P.396, N.397, R.398 4 PLIP interactions: 4 interactions with chain A Hydrogen bonds: A:T.395, A:N.397, A:N.397, A:R.398

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Ishchenko, A. et al., Toward G protein-coupled receptor structure-based drug design using X-ray lasers. Iucrj (2019)

Release Date

2019-11-13

Peptides

Fusion protein of Beta-2 adrenergic receptor and T4 Lysozyme: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Membrane

We predict this structure to be a membrane protein.
Show / Hide

Fusion protein of Beta-2 adrenergic receptor and T4 Lysozyme

Related Entries With Identical Sequence